Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry

AIMS: The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure Managemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeymer, Uwe, Clark, Andrew L., Barrios, Vivencio, Damy, Thibaud, Drożdż, Jaroslaw, Fonseca, Candida, Lund, Lars H., Comite, Gabriele Di, Hupfer, Stephan, Maggioni, Aldo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Study Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160498/
https://www.ncbi.nlm.nih.gov/pubmed/32027782
http://dx.doi.org/10.1002/ehf2.12569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160498/
https://www.ncbi.nlm.nih.gov/pubmed/32027782
http://dx.doi.org/10.1002/ehf2.12569

Ejemplares similares